PRESS RELEASES

• Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

  January 17, 2019
• Promentis Pharmaceuticals to present at the 57th annual American College of Neuropsychopharmacology (ACNP) meeting

  December 5, 2018
• Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

  November 16, 2018
• Promentis Pharmaceuticals to present at the Society for Neuroscience conference

  October 29, 2018